# A Bloomberg report indicated that the Trump administration is planning tariffs on pharmaceutical companies that have not entered into agreements to ensure lower drug prices in the US.

*biotech · news · 2026-04-02 · CNBC TV18*

## Key points

- The Trump administration is considering tariffs up to 100% on imported branded and patented medicines.
- Companies with US drug pricing agreements or participation in TrumpRx.gov have avoided proposed tariffs.
- Sun Pharma faces heightened risk due to its significant US branded drug exposure and lack of agreement.
- Pfizer, AstraZeneca, Roche, Novartis, Eli Lilly, Johnson & Johnson, Merck, Novo Nordisk, and GSK have secured tariff waivers through agreements.

**Companies:** Pfizer, AstraZeneca, Roche, Johnson & Johnson, Novartis, Eli Lilly, Merck, Novo Nordisk, GSK, Sun Pharmaceutical Industries
**Countries:** United States, India

[Read the full story on CNBC TV18](https://www.cnbctv18.com/market/nifty-pharma-index-drops-sun-pharma-cipla-dr-reddy-zydus-life-shares-as-us-tariff-fears-hit-ws-l-19879565.htm)

---

Canonical: https://newsio.io/n/e1f898ca-74f4-4145-a208-86bea9c39ac5/a-bloomberg-report-indicated-that-the-trump-administration-is-planning-tariffs-o
Summarized by Newsio from CNBC TV18. https://newsio.io/how-it-works